Suven Life Sci 
Welcome,         Profile    Billing    Logout  
 5 Products   1 Disease   5 Products   5 Trials   210 News 


123»
  • ||||||||||  masupirdine (SUVN-502) / Suven Life Sci
    Trial completion date, Trial primary completion date:  Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type (clinicaltrials.gov) -  May 20, 2025   
    P3,  N=375, Recruiting, 
    Trial completion date: Jan 2025 --> Dec 2025 | Trial primary completion date: Jan 2025 --> Dec 2025
  • ||||||||||  masupirdine (SUVN-502) / Suven Life Sci
    Journal:  Drug Development. (Pubmed Central) -  Jan 12, 2025   
    P2a, P3
    The Phase-3 study results may inform the therapeutic utility of masupirdine for the treatment of Alzheimer's agitation. Phase-3 study data readout is anticipated in Q1/Q2 2025.
  • ||||||||||  ropanicant (SUVN-911) / Suven Life Sci
    Enrollment closed:  Study Evaluating Safety and Efficacy of Ropanicant in MDD Patients (clinicaltrials.gov) -  May 30, 2024   
    P2,  N=41, Active, not recruiting, 
    Phase-3 study data readout is anticipated in Q1/Q2 2025. Recruiting --> Active, not recruiting
  • ||||||||||  ropanicant (SUVN-911) / Suven Life Sci
    Effect of Ropanicant (SUVN-911), an ?4?2 Receptor Antagonist in Animal Models of Depression (Salon 4) -  Apr 29, 2024 - Abstract #ASCP2024ASCP_259;    
    P2
    Learning Objectives 1.Evaluate the non-clinical efficacy of ropanicant an ?4?2 receptor antagonist in animal models of depression. 2.To understand the differentiating features of ropanicant over current standards of care with respect to onset of action and side effects profile
  • ||||||||||  ropanicant (SUVN-911) / Suven Life Sci
    Enrollment open:  Study Evaluating Safety and Efficacy of Ropanicant in MDD Patients (clinicaltrials.gov) -  Jan 23, 2024   
    P2,  N=36, Recruiting, 
    Samelisant could be a potential new therapy for the management of narcolepsy Not yet recruiting --> Recruiting
  • ||||||||||  masupirdine (SUVN-502) / Suven Life Sci
    Masupirdine (SUVN-502), a pure 5-HT6 receptor antagonist: Rationale for evaluation in patients with agitation in dementia of Alzheimer's type (WCC Halls A-C) -  Nov 3, 2023 - Abstract #Neuroscience2023NEUROSCIENCE_7246;    
    P2a, P3
    In addition, masupirdine significantly modulated levels of dopamine and norepinephrine in brain at a dose of 10 mg/kg, s.c. The post hoc analysis of the Phase-2 study (NCT02580305) in patients with moderate AD suggested treatment with masupirdine at 50 mg and 100 mg significantly decreased the agitation/aggression score from Week 13 to Week 26 suggesting potential treatment effects of masupirdine on agitation/aggression symptoms. To explore the beneficial effects, masupirdine is currently being evaluated as a monotherapy in a global Phase-3 study for the potential treatment of agitation in participants with dementia of Alzheimer's type (NCT05397639).
  • ||||||||||  masupirdine (SUVN-502) / Suven Life Sci, Rexulti (brexpiprazole) / Lundbeck, Otsuka
    Journal:  A 2023 update on the advancements in the treatment of agitation in Alzheimer's disease. (Pubmed Central) -  Apr 21, 2023   
    Clinical trials remain underway utilizing both novel and repurposed agents to address symptoms of agitation in AD. With increasing understanding of the neurobiological mechanisms that fuel the development of agitation in AD, the use of enhanced trial design and conduct, advanced statistical approaches, and accelerated pathways for regulatory approval, we are advancing closer to having safe and efficacious treatment options for agitation in AD.
  • ||||||||||  masupirdine (SUVN-502) / Suven Life Sci
    Trial initiation date:  Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type (clinicaltrials.gov) -  Aug 31, 2022   
    P3,  N=375, Recruiting, 
    Ropanicant pharmacokinetics were sex dependent, and food and age had no effect on its pharmacokinetics. Initiation date: Jun 2022 --> Sep 2022